Clinical Trial Update: Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing apatinib alone versus apatinib plus camrelizumab as third-line therapy for metastatic gastric cancer is in progress with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Fudan University | Conditions: Gastric Cancer, Metastasis | Phase 2 | Status: UNKNOWN